MedTrace Logo

Rollover Study Of Lapatinib In Cancer Patients

NCT00169533 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-11-17

No results posted yet for this study

Summary

The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is available pending FDA approval.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

GW572016 oral tablets

Lapatinib either at 750, 1000, 1250 or 1500 mgs

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-19
Primary Completion
2009-05-05
Completion
2009-05-05

Countries

  • United States
  • Canada
  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169533 on ClinicalTrials.gov